# Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

> **NCT05286528** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1484 (actual)

## Conditions studied

- Chronic Myeloid Leukaemia

## Interventions

- **DRUG:** Bosutinib
- **DRUG:** Imatinib
- **DRUG:** Nilotinib
- **DRUG:** Dasatinib
- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT05286528
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-18
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 1484 (ACTUAL)
- **Last updated:** 2023-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286528, "Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05286528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*